Alumis Inc. Common Stock ALMS
$6.70
+5.68%
at last close
Market Cap$867.22 million
P/E Ratio—
Div Yield—
Volume1.54M
52-Week Range
$3.76$31.35
Analyst Ratings
- Consensus
- Buy — 8 Buy · 1 Hold · 0 Sell (9 analysts)
- Avg. Price Target
- $33.50 (+400.0% upside)
Key Stats
- Today's Range
- $6.25 – $6.72
- 50-Day Range
- $6.01 – $27.69
- 52-Week Range
- $3.76 – $31.35
- Volume
- 1.54 million shs
- Average Volume
- 2.77 million shs
- Market Cap
- $867.22 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.47%
- Days to Cover
- 3.15
About Alumis Inc. Common Stock
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Related Stocks
Compare head-to-head: ALMS vs LLY·ALMS vs JNJ·ALMS vs ABBV·ALMS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.